IMPACT
gene geneOn this page
Also known as RWDD5
Summary
IMPACT (impact RWD domain protein, HGNC:20387) is a protein-coding gene on chromosome 18q11.2, encoding Protein IMPACT (Q9P2X3). Translational regulator that ensures constant high levels of translation upon a variety of stress conditions, such as amino acid starvation, UV-C irradiation, proteasome inhibitor treatment and glucose deprivation.
Predicted to enable protein sequestering activity. Predicted to be involved in several processes, including GCN2-mediated signaling; cellular response to amino acid starvation; and regulation of gene expression. Predicted to act upstream of or within negative regulation of protein phosphorylation. Predicted to be active in cytoplasm.
Source: NCBI Gene 55364 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 31 total
- MANE Select transcript:
NM_018439
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20387 |
| Approved symbol | IMPACT |
| Name | impact RWD domain protein |
| Location | 18q11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | RWDD5 |
| Ensembl gene | ENSG00000154059 |
| Ensembl biotype | protein_coding |
| OMIM | 615319 |
| Entrez | 55364 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 10 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron
ENST00000284202, ENST00000578221, ENST00000580035, ENST00000580706, ENST00000581278, ENST00000585067, ENST00000648078, ENST00000896352, ENST00000896353, ENST00000896354, ENST00000896355, ENST00000936943
RefSeq mRNA: 1 — MANE Select: NM_018439
NM_018439
CCDS: CCDS11886
Canonical transcript exons
ENST00000284202 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001237891 | 24450779 | 24453531 |
| ENSE00001237900 | 24426670 | 24426792 |
| ENSE00003488586 | 24449819 | 24449953 |
| ENSE00003507538 | 24440496 | 24440618 |
| ENSE00003522078 | 24448093 | 24448183 |
| ENSE00003547033 | 24427919 | 24428047 |
| ENSE00003550006 | 24445393 | 24445466 |
| ENSE00003575407 | 24437955 | 24438040 |
| ENSE00003668936 | 24428869 | 24428921 |
| ENSE00003681669 | 24430322 | 24430384 |
| ENSE00003789552 | 24443049 | 24443152 |
Expression profiles
Bgee: expression breadth ubiquitous, 277 present calls, max score 95.04.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.7460 / max 138.9342, expressed in 1755 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 169742 | 13.5288 | 1743 |
| 169741 | 9.5124 | 1702 |
| 169740 | 0.7048 | 371 |
Top tissues by expression
289 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| calcaneal tendon | UBERON:0003701 | 95.04 | gold quality |
| adrenal tissue | UBERON:0018303 | 91.43 | gold quality |
| ventricular zone | UBERON:0003053 | 91.29 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 91.00 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 89.05 | gold quality |
| islet of Langerhans | UBERON:0000006 | 88.98 | gold quality |
| monocyte | CL:0000576 | 88.66 | gold quality |
| mononuclear cell | CL:0000842 | 88.30 | gold quality |
| stromal cell of endometrium | CL:0002255 | 88.00 | gold quality |
| leukocyte | CL:0000738 | 87.79 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 86.58 | gold quality |
| ganglionic eminence | UBERON:0004023 | 86.51 | gold quality |
| rectum | UBERON:0001052 | 86.23 | gold quality |
| tibia | UBERON:0000979 | 86.15 | gold quality |
| left adrenal gland | UBERON:0001234 | 86.10 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 86.10 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 85.88 | gold quality |
| hypothalamus | UBERON:0001898 | 85.84 | gold quality |
| endothelial cell | CL:0000115 | 85.80 | gold quality |
| right adrenal gland | UBERON:0001233 | 85.72 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 85.70 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 85.64 | gold quality |
| adrenal gland | UBERON:0002369 | 85.62 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 85.34 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 85.13 | gold quality |
| nasopharynx | UBERON:0001728 | 85.12 | gold quality |
| eye | UBERON:0000970 | 84.70 | gold quality |
| popliteal artery | UBERON:0002250 | 84.63 | gold quality |
| tibial artery | UBERON:0007610 | 84.63 | gold quality |
| testis | UBERON:0000473 | 84.55 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.96 |
| E-MTAB-6058 | no | 305.08 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): MYC
miRNA regulators (miRDB)
142 targeting IMPACT, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-5692B | 100.00 | 71.32 | 2622 |
| HSA-MIR-5692C | 100.00 | 71.32 | 2622 |
| HSA-MIR-4673 | 100.00 | 66.64 | 1490 |
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-513B-5P | 99.99 | 69.96 | 2150 |
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-4531 | 99.99 | 69.70 | 3181 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-4645-5P | 99.98 | 65.81 | 1284 |
| HSA-MIR-3688-3P | 99.97 | 72.02 | 2834 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-144-3P | 99.94 | 73.98 | 2698 |
Literature-anchored findings (GeneRIF, showing 3)
- It thus seems that lineage-specific enhancement of gene expression rather than the tandem repeat per se played a critical role in the evolution of imprinting of Impact. (PMID:15752730)
- segmental duplication followed by enhancement of the promoter activity is responsible for the species-specific imprinting of Impact (PMID:15871461)
- Data suggest that high expression of protein IMPACT homolog in non-immune cells acts as a protective mechanism against indoleamine 2,3-dioxygenase (IDO)-induced GCN2 activation, making them resistant to the amino acid-deprived environment caused by IDO. (PMID:20648630)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | impact | ENSDARG00000043288 |
| mus_musculus | Impact | ENSMUSG00000024423 |
| rattus_norvegicus | Impact | ENSRNOG00000045844 |
| caenorhabditis_elegans | impt-1 | WBGENE00013122 |
Protein
Protein identifiers
Protein IMPACT — Q9P2X3 (reviewed: Q9P2X3)
Alternative names: Imprinted and ancient gene protein homolog
All UniProt accessions (6): Q9P2X3, A0A3B3ITH3, J3KT25, J3QLU6, J3QQU0, J3QRS6
UniProt curated annotations — full annotation on UniProt →
Function. Translational regulator that ensures constant high levels of translation upon a variety of stress conditions, such as amino acid starvation, UV-C irradiation, proteasome inhibitor treatment and glucose deprivation. Plays a role as a negative regulator of the EIF2AK4/GCN2 kinase activity; impairs GCN1-mediated EIF2AK4/GCN2 activation, and hence EIF2AK4/GCN2-mediated eIF-2-alpha phosphorylation and subsequent down-regulation of protein synthesis. May be required to regulate translation in specific neuronal cells under amino acid starvation conditions by preventing GCN2 activation and therefore ATF4 synthesis. Through its inhibitory action on EIF2AK4/GCN2, plays a role in differentiation of neuronal cells by stimulating neurite outgrowth.
Subunit / interactions. Interacts with GCN1; prevents the interaction of GCN1 with EIF2AK4/GCN2 and inhibits EIF2AK4/GCN2 kinase activity. Interaction with RPL39; this interaction occurs in a GCN1-independent manner. Associates with ribosomes; this interaction occurs in a GCN1-independent manner. Associates with actin; this interaction occurs in a GCN1-independent manner.
Subcellular location. Cytoplasm.
Tissue specificity. Widely expressed. Expressed at high level in brain.
Miscellaneous. In contrast to the mouse or rabbit ortholog, the IMPACT locus is not imprinted in human.
Similarity. Belongs to the IMPACT family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9P2X3-1 | 1 | yes |
| Q9P2X3-2 | 2 |
RefSeq proteins (1): NP_060909* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001498 | Impact_N | Domain |
| IPR006575 | RWD_dom | Domain |
| IPR016135 | UBQ-conjugating_enzyme/RWD | Homologous_superfamily |
| IPR020568 | Ribosomal_Su5_D2-typ_SF | Homologous_superfamily |
| IPR020569 | UPF0029_Impact_CS | Conserved_site |
| IPR023582 | Impact | Family |
| IPR036956 | Impact_N_sf | Homologous_superfamily |
Pfam: PF01205, PF05773
UniProt features (9 total): sequence variant 3, chain 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9P2X3-F1 | 80.56 | 0.61 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 297
Function
Pathways and Gene Ontology
Reactome pathways
4 pathways
| ID | Pathway |
|---|---|
| R-HSA-9633012 | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| R-HSA-2262752 | Cellular responses to stress |
| R-HSA-8953897 | Cellular responses to stimuli |
| R-HSA-9711097 | Cellular response to starvation |
MSigDB gene sets: 233 (showing top):
GOBP_CYTOPLASMIC_TRANSLATION, GOBP_REGULATION_OF_TRANSLATION_IN_RESPONSE_TO_STRESS, GOBP_NEURON_PROJECTION_EXTENSION, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_POSITIVE_REGULATION_OF_NEURON_DIFFERENTIATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_GROWTH, GOBP_TRANSLATIONAL_INITIATION, GOBP_NEUROGENESIS, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, MARTINEZ_RB1_TARGETS_DN, GOBP_REGULATION_OF_NEURON_DIFFERENTIATION
GO Biological Process (11): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of translational initiation (GO:0006446), cellular response to amino acid starvation (GO:0034198), intracellular signal transduction (GO:0035556), positive regulation of neuron differentiation (GO:0045666), GCN2-mediated signaling (GO:0140469), neuron projection extension (GO:1990138), regulation of cytoplasmic translational initiation in response to stress (GO:1990611), regulation of translation (GO:0006417), nervous system development (GO:0007399), cell differentiation (GO:0030154)
GO Molecular Function (4): actin binding (GO:0003779), ribosome binding (GO:0043022), protein sequestering activity (GO:0140311), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
Reactome top-level categories
Rollup of top-3 pathways:
| Category | Pathways |
|---|---|
| Cellular response to starvation | 1 |
| Cellular responses to stimuli | 1 |
| Cellular responses to stress | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular anatomical structure | 2 |
| regulation of transcription by RNA polymerase II | 1 |
| transcription by RNA polymerase II | 1 |
| negative regulation of DNA-templated transcription | 1 |
| translational initiation | 1 |
| regulation of translation | 1 |
| cellular response to starvation | 1 |
| response to amino acid starvation | 1 |
| signal transduction | 1 |
| neuron differentiation | 1 |
| positive regulation of cell differentiation | 1 |
| regulation of neuron differentiation | 1 |
| integrated stress response signaling | 1 |
| developmental cell growth | 1 |
| neuron projection morphogenesis | 1 |
| developmental growth involved in morphogenesis | 1 |
| cytoplasmic translational initiation | 1 |
| cellular response to stress | 1 |
| regulation of translational initiation in response to stress | 1 |
| regulation of cytoplasmic translational initiation | 1 |
| regulation of cytoplasmic translation in response to stress | 1 |
| translation | 1 |
| post-transcriptional regulation of gene expression | 1 |
| regulation of protein metabolic process | 1 |
| system development | 1 |
| cellular developmental process | 1 |
| cytoskeletal protein binding | 1 |
| ribonucleoprotein complex binding | 1 |
| protein binding | 1 |
| molecular sequestering activity | 1 |
| binding | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
700 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| IMPACT | GCN1 | Q92616 | 535 |
| IMPACT | EIF2AK4 | Q9P2K8 | 529 |
| IMPACT | FBXO28 | Q9NVF7 | 489 |
| IMPACT | RWDD1 | Q9H446 | 352 |
| IMPACT | ATXN2L | Q8WWM7 | 347 |
| IMPACT | ATXN2 | Q99700 | 347 |
| IMPACT | KARS1 | Q15046 | 299 |
| IMPACT | GGA2 | Q9UJY4 | 289 |
| IMPACT | FRYL | O94915 | 286 |
| IMPACT | RWDD4 | Q6NW29 | 284 |
| IMPACT | IMPA2 | O14732 | 280 |
| IMPACT | IMPA1 | P29218 | 280 |
| IMPACT | ABCF3 | Q9NUQ8 | 278 |
| IMPACT | GGA3 | Q9NZ52 | 268 |
| IMPACT | HRH4 | Q9H3N8 | 267 |
IntAct
47 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CA10 | WDHD1 | psi-mi:“MI:0914”(association) | 0.640 |
| HRG | PLSCR1 | psi-mi:“MI:0914”(association) | 0.590 |
| SERPINF1 | IMPACT | psi-mi:“MI:0915”(physical association) | 0.560 |
| PSMB1 | IMPACT | psi-mi:“MI:0915”(physical association) | 0.560 |
| RRP8 | MAGEB2 | psi-mi:“MI:0914”(association) | 0.530 |
| IMPACT | CRHBP | psi-mi:“MI:0915”(physical association) | 0.400 |
| Shoc2 | GABPB1 | psi-mi:“MI:0914”(association) | 0.350 |
| Dync1li1 | SSR3 | psi-mi:“MI:0914”(association) | 0.350 |
| Bub1 | PEX10 | psi-mi:“MI:0914”(association) | 0.350 |
| Bub1b | ASAH1 | psi-mi:“MI:0914”(association) | 0.350 |
| Naa10 | MYO9A | psi-mi:“MI:0914”(association) | 0.350 |
| CDC73 | SCAMP3 | psi-mi:“MI:0914”(association) | 0.350 |
| SGO1 | ELOC | psi-mi:“MI:0914”(association) | 0.350 |
| LLGL2 | RBBP6 | psi-mi:“MI:0914”(association) | 0.350 |
| Pafah1b1 | ATXN3 | psi-mi:“MI:0914”(association) | 0.350 |
| Poc1a | SQSTM1 | psi-mi:“MI:0914”(association) | 0.350 |
| KIF20B | ACSL3 | psi-mi:“MI:0914”(association) | 0.350 |
| KIF7 | TBC1D31 | psi-mi:“MI:0914”(association) | 0.350 |
| Hnrnpa3 | MATR3 | psi-mi:“MI:0914”(association) | 0.350 |
| CRKL | SOS1 | psi-mi:“MI:0914”(association) | 0.350 |
| ETS2 | ANKS6 | psi-mi:“MI:0914”(association) | 0.350 |
| Vps4b | CNOT1 | psi-mi:“MI:0914”(association) | 0.350 |
| Chmp6 | NSF | psi-mi:“MI:0914”(association) | 0.350 |
| REEP5 | CNOT1 | psi-mi:“MI:0914”(association) | 0.350 |
| BTBD8 | HSPA8 | psi-mi:“MI:0914”(association) | 0.350 |
| FANCI | FAAP20 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (52): IMPACT (Biochemical Activity), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS), IMPACT (Affinity Capture-MS)
ESM2 similar proteins: A1A5G2, A6H7H7, A7YY45, A9UMG5, E1C3P4, O55091, O55236, O60942, P49754, P54731, P69341, Q08J23, Q14457, Q149N8, Q15650, Q1RMU2, Q28GH3, Q4A1L3, Q569B7, Q5GFD8, Q5GFD9, Q5M8G6, Q5R878, Q5RED8, Q5U252, Q5ZKY2, Q5ZLV4, Q642J4, Q66H62, Q6GP52, Q6GR37, Q6NY98, Q80TQ2, Q8QFR2, Q90ZA1, Q91XL9, Q96DT6, Q9BXW6, Q9CPR1, Q9ESL4
Diamond homologs: A7YY45, A9UMG5, F1RB95, O13997, O55091, O60090, P25637, P32437, P32438, Q12257, Q54JW9, Q5GFD8, Q5GFD9, Q5M8G6, Q642J4, Q9P2X3, Q9W625, Q9XWF4, Q9UBS8, Q9JI90, P27862, P44842
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| SMURF1 | unknown | IMPACT | ubiquitination |
Disease & clinical
Clinical variants and AI predictions
ClinVar
31 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 17 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2182 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 18:24427913:TTTCA:T | acceptor_loss | 1.0000 |
| 18:24427914:TTCA:T | acceptor_loss | 1.0000 |
| 18:24427916:CAGA:C | acceptor_loss | 1.0000 |
| 18:24427917:A:AG | acceptor_gain | 1.0000 |
| 18:24427918:G:GA | acceptor_gain | 1.0000 |
| 18:24427918:GA:G | acceptor_gain | 1.0000 |
| 18:24427918:GAA:G | acceptor_gain | 1.0000 |
| 18:24427918:GAAT:G | acceptor_gain | 1.0000 |
| 18:24428047:GG:G | donor_loss | 1.0000 |
| 18:24428922:G:GG | donor_gain | 1.0000 |
| 18:24430320:A:AG | acceptor_gain | 1.0000 |
| 18:24430321:G:GG | acceptor_gain | 1.0000 |
| 18:24430321:GT:G | acceptor_gain | 1.0000 |
| 18:24430385:G:GG | donor_gain | 1.0000 |
| 18:24437953:A:AG | acceptor_gain | 1.0000 |
| 18:24437954:G:GA | acceptor_gain | 1.0000 |
| 18:24437954:GTCA:G | acceptor_gain | 1.0000 |
| 18:24440491:C:G | acceptor_gain | 1.0000 |
| 18:24440492:A:AG | acceptor_gain | 1.0000 |
| 18:24440492:ATAG:A | acceptor_gain | 1.0000 |
| 18:24440493:T:G | acceptor_gain | 1.0000 |
| 18:24440494:A:AG | acceptor_gain | 1.0000 |
| 18:24440494:A:T | acceptor_loss | 1.0000 |
| 18:24440495:G:GT | acceptor_gain | 1.0000 |
| 18:24440495:GGC:G | acceptor_gain | 1.0000 |
| 18:24440495:GGCCC:G | acceptor_gain | 1.0000 |
| 18:24440571:A:T | donor_gain | 1.0000 |
| 18:24440614:GACAG:G | donor_gain | 1.0000 |
| 18:24440618:GG:G | donor_loss | 1.0000 |
| 18:24440619:G:C | donor_loss | 1.0000 |
AlphaMissense
2140 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 18:24428906:C:A | P68H | 1.000 |
| 18:24443108:A:C | S184R | 1.000 |
| 18:24443110:T:A | S184R | 1.000 |
| 18:24443110:T:G | S184R | 1.000 |
| 18:24445442:C:A | A215D | 1.000 |
| 18:24448155:C:A | A244D | 1.000 |
| 18:24449858:T:A | W267R | 1.000 |
| 18:24449858:T:C | W267R | 1.000 |
| 18:24449865:G:A | G269E | 1.000 |
| 18:24449891:T:C | F278L | 1.000 |
| 18:24449893:T:A | F278L | 1.000 |
| 18:24449893:T:G | F278L | 1.000 |
| 18:24427943:G:C | A21P | 0.999 |
| 18:24427961:T:A | W27R | 0.999 |
| 18:24427961:T:C | W27R | 0.999 |
| 18:24428887:T:C | Y62H | 0.999 |
| 18:24428888:A:G | Y62C | 0.999 |
| 18:24428906:C:G | P68R | 0.999 |
| 18:24437986:T:A | W105R | 0.999 |
| 18:24437986:T:C | W105R | 0.999 |
| 18:24443103:G:C | R182P | 0.999 |
| 18:24443114:T:C | F186L | 0.999 |
| 18:24443115:T:C | F186S | 0.999 |
| 18:24443116:T:A | F186L | 0.999 |
| 18:24443116:T:G | F186L | 0.999 |
| 18:24445447:C:G | H217D | 0.999 |
| 18:24445460:C:A | A221D | 0.999 |
| 18:24448158:G:A | G245D | 0.999 |
| 18:24448167:T:C | L248P | 0.999 |
| 18:24448170:T:C | L249P | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000049170 (18:24450655 A>G), RS1000055527 (18:24431950 C>T), RS1000106015 (18:24449117 T>C), RS1000152760 (18:24436881 A>G), RS1000259593 (18:24443217 A>G), RS1000269298 (18:24425089 T>A,C), RS1000282848 (18:24430047 G>T), RS1000357517 (18:24437274 A>G), RS1000402162 (18:24450349 G>A), RS1000421061 (18:24430264 A>G), RS1000630191 (18:24441654 A>G), RS1000636734 (18:24426484 C>A,G,T), RS1000698220 (18:24442918 A>G), RS1000703374 (18:24425310 C>G,T), RS1000756701 (18:24447723 G>A)
Disease associations
OMIM: gene MIM:615319 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
28 total (human), top 28 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 2 |
| Tetrachlorodibenzodioxin | decreases expression | 2 |
| Valproic Acid | increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| GSK-J4 | decreases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| arsenite | increases reaction, affects binding | 1 |
| manganese chloride | affects cotreatment, increases abundance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | increases reaction, affects binding | 1 |
| 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | increases response to substance, increases expression | 1 |
| Resveratrol | affects cotreatment, increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Fulvestrant | increases methylation | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium | increases expression | 1 |
| Manganese | affects cotreatment, increases abundance, increases expression | 1 |
| Plant Extracts | affects cotreatment, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Thiram | decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Cyclosporine | increases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.